Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXEL – Research Report), Intellia Therapeutics (NTLA – Research Report) and Sarepta Therapeutics (SRPT – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exelixis (EXEL)
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Exelixis, with a price target of $36.00. The company’s shares closed last Monday at $41.03.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $46.67, which is an 11.1% upside from current levels. In a report issued on February 17, RBC Capital also maintained a Hold rating on the stock with a $46.00 price target.
See today’s best-performing stocks on TipRanks >>
Intellia Therapeutics (NTLA)
In a report released yesterday, Brian Cheng from J.P. Morgan reiterated a Sell rating on Intellia Therapeutics. The company’s shares closed last Monday at $15.44.
According to TipRanks.com, Cheng is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $21.17 average price target.
Sarepta Therapeutics (SRPT)
In a report released today, Anupam Rama from J.P. Morgan maintained a Hold rating on Sarepta Therapeutics. The company’s shares closed last Monday at $16.32.
According to TipRanks.com, Rama is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $21.06 average price target, implying a 29.4% upside from current levels. In a report issued on February 25, Goldman Sachs also maintained a Hold rating on the stock with a $17.00 price target.
